Is there a relationship between HLA type and prognostic factors in breast cancer?

Anticancer Research

Volumn 23, Issue 1 B, 2003, Pages 633-638

  Gourley, Charles ^a,e   Thornton, C ^c   Massie, C ^a   Prescott, R J ^b   Turner, M ^c   Leonard, R C F ^d   Kilpatrick, D C ^c  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

^d SWANSEA UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Breast cancer; Breast carcinoma; HLA; Human leucocyte antigen; Immunotherapy; Major histocompatibility complex; MHC

Indexed keywords

ESTROGEN RECEPTOR; HLA A1 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B7 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; BLOOD SAMPLING; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GRADING; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HLA TYPING; HUMAN; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PARAMETER; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-DR ANTIGENS; HUMANS; MIDDLE AGED; PROGNOSIS; RECEPTORS, ESTROGEN;

EID: 0037231142     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Goldhirsch A, Glick G, Gelber R, Coates A and Senn HJ: Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Clin Oncol 19: 3817-3827, 2001.
2. Fischer B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerman D, Bryant J, Dimitrov N, Abramson N, Atkins J, Shibata H, Deschenes L and Margolese R: Tamoxifen and chemotherapy for lymphnode-negative, oestrogen receptor-positive breast cancer. J Natl Cancer Inst 89: 1673-82, 1997.
3. Valero V: Primary chemotherapy with docetaxel for the management of breast cancer. Oncology 16: 35-43, 2002.
4. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub J, Cervantes G, Fumoleau P, Jones S, Lui W, Mauriac L, Twelves C, Van Hazel G, Verma S and Leonard R: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812-23, 2002.
5. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, Kellokumpu-Lehtinen P, Bengtsson NO, Soderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C and Wilking N: Tailored fluorouracil, epirubicin and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. The Lancet 356: 1384-1391, 2000.
6. Hortobagyi G, Buzdar A, Theriault R, Valero V, Frye D, Booser D, Holmes F, Giralt S, Khouri I, Andersson B, Gajewski J, Rondon G, Smith, T Singletary S, Ames F, Sneige N, Strom E, McNeese M, Deisseroth A and Champlin R: Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Nat Canc Instit 92: 1271-2, 2000.
7. Coley W: The treatment of malignant tumours by repeated inoculations of erysipelas: with a report of 10 original cases. Am J Med Sciences 105: 487-511, 1893.
8. Cabrera T, Angustias Fernandez M, Sierra A, Garrido A, Herruzo A, Escobedo A, Fabra A and Garrido F: High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol 50: 127-34, 1996.
9. Concha A, Cabrera T, Ruiz-Cabello F and Garrido F: Can the HLA phenotype be used as a prognostic factor in breast carcinomas? Int J Cancer Suppl 6: 146-54, 1991.
10. Goepel JR, Rees RC, Rogers K, Stoddard CJ, Thomas WE and Shepherd L: Loss of monomorphic and polymorphic HLA antigens in metastatic breast and colon carcinoma. Br J Cancer 64: 880-3, 1991.
11. Gudmundsdottir I, Jonasson JG, Sigurdsson H, Olafsdottir K, Tryggvadottir L and Ogmundsdottir HM: Altered expression of HLA class I antigens in breast cancer: an association with prognosis. Internat J Cancer (Predictive Oncology) 89: 500-505, 2000.
12. Hammond MG, Appadoo B and Brain P: HLA and cancer in South African Indians. Tissue Antigens 14: 296-302, 1979.
13. Lindenberg P, Walter H and Zockler H: Association of major histocompatibility complex antigens (HLA antigens) and breast carcinoma. Anthropol Anz 44: 335-40, 1986.
14. Yokoe T, Ishida T, Ogawa T, Iino Y and Izuo M: Relationship of breast cancer and HLA in Japanese females. Gan No Rinsho 36: 29-33, 1990.
15. Subira M, Criscj C and Zoruosa G: Breast cancer and histocompatibility antigens. Allergol Immunopathol 7: 411-416, 1979.
16. Perdue ST, Terasaki PI and Mickey MR: HLA frequencies in cancer: a third study. IARC Sci Publ 20: 263-9, 1978.
17. Bouillenne C and Deneufbourg, JM: Positive correlation between breast cancer incidence and HLA antigens. Oncology 36: 156-9, 1979.
18. Casoli C, Zanelli P, Adorni A, Starcich BR and Neri T: Serological and molecular study on the HLA phenotype of female breast cancer patients. Eur J Cancer 8: 1207-8, 1994.
19. Garam T, Gyodi E, Bakacs T, Svastits E and Petranyi G: Incidence of HLA-antigens and cytotoxic capacity of lymphocytes in patients with breast cancer. Orv Hetil 121: 2323-6, 1980.
20. Song ST: Association of HLA with breast cancer and its ER status. Zhonghua Zhong Liu Za Zhi 11: 19-21, 1989.
21. Abrahamova J and Majsky A: HLA system and some neoplastic diseases. Acta Univ Carol Med Monogr 123: 1-80, 1988.
22. Martz E and Benacerraf B: Lack of association between carcinoma of the breast and HL-A specificities. Tissue Antigens 3: 30-38, 1973.
23. Cordon A and James D: HL-A and carcinoma of the breast. Lancet 565, 1973.
24. De Jong-Bakker M, Cleton F, D'Amaro J, Keuning J and Van Rood J: HL-A antigens and breast cancer. Eur J Cancer 10: 555-558, 1974.
25. Patel R, Habal M, Wilson R, Birtch A and Moore F: Histocompatibility (HLA) antigens and cancer of the breast. Am J Surg 124: 31-34, 1972.
26. Rosenberg SA: Progress in human tumour immunology and immunotherapy. Nature 411: 380-384, 2001.
27. Lazarro B, Anderson A, Kajdacsy-Balla A and Hessner M: Antigenic characterisation of medullary carcinoma of the breast: HLA-DR expression in lymph node positive cases. Appl Immunohistochem and Molecul Morphol 9: 234-41, 2001.
28. Chaudhuri S, Cariappa A, Tang M, Bell D, Haber D, Isselbacher K, Finkelstein D, Forcione D and Pillai S: Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles. PNAS 97: 11451-11454, 2000.
29. Iaffaioli RV, Maio M, Ruggiero G, De Felice M, Ungaro A, Del Vecchio L, Rosato GB, Bianco AR and Zappacosta S: HLA and prognostic factors in primary breast cancer. Int J Cancer 35: 581-5, 1985.
30. Feingold N, Degos L and Feingold J: HLA in populations: an approach for genetical susceptibility to cancer. J Immunogenet 6: 29-35, 1979.
31. Meyer zum Buschenfelde C, Hermann C, Schmidt B, Peschel C and Bernhard H: Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res 62: 2244-2247, 2002.
32. Sotiriadou R, Perez S, Gritzapis A, Sotiropoulou P, Echner H, Heinzel S, Mamalaki A, Pawelec G, Voelter W, Baxevanis C and Papamichail M: Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope. Brit J Canc 85: 1527-34, 2001.
33. Blamey R: The design and clinical use of Nottingham Prognostic Index in breast cancer. The Breast 5: 156-7, 1996.
34. Kilpatrick D and Darg C: Enzymatic modification of the lymphocyte surface. Application to tissue typing and rosetting with sheep erythrocytes,. Tissue Antigens 21: 309-317, 1983.
35. Tiwari J and Terasaki P: HLA and Disease Associations, pp. 14-17. New York: Springer-Verlag, 1985.
36. Olerup O and Zetterquist H: HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 39: 225-235, 1992.
37. Olerup O and Zetterquist H: DR "low resolution" PCR-SSP typing - a correction and update. Tissue Antigens 41: 55-56, 1993.